Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying
NCT ID: NCT01910194
Last Updated: 2015-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
39 participants
INTERVENTIONAL
2013-12-31
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus
NCT01600950
Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1
NCT01146678
A Study in Adults With Type 1 Diabetes
NCT01421147
Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)
NCT00653302
A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants
NCT03555305
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lyxumia
4 weeks Luxumia plus another 4 weeks combination
Luyxumia versus Lantus
Lantus
4 weeks Lantus plus another 4 weeks combination
Luyxumia versus Lantus
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Luyxumia versus Lantus
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Inadequately controlled diabetes mellitus
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Profil Institut für Stoffwechselforschung GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Josef-Hospital, University Hospital, Ruhr
Bochum, , Germany
Profil Institut für Stoffwechselforschung GmbH
Neuss, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LanLyx
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.